Nakajima and colleagues identified MYBL2 as a probable transcriptional target of E2F1 in HCC and as a useful biomarker for diagnosis and an attractive target for molecular therapies useful to treat HCC [29]. The gene discussed is E2F1; the disease is hepatocellular carcinoma.